20Jan Rep. Franz welcomes granddaughter to State of the State address Categories: Featured news,News Tags: #SB, Franz, HD101, MISOTS16 LANSING, MI – Onekama lawmaker State Rep. Ray Franz, right, welcomed granddaughter Meghan Franz, left, to the House chamber tonight to hear Gov. Rick Snyder’s State the State address.“It is a true blessing to have my granddaughter here with me tonight to share in this experience,” Rep. Franz said. “Like so many Michigan families across the state, family comes first and my family means everything to me. This is also a great opportunity for Meghan to see what her grandpa really does in Lansing. This will be the last address I attend in the House chambers as state representative and I couldn’t think of a better person I’d rather have at my side than Meghan.”Meghan Franz is originally from Toledo, Ohio and is currently a sophomore at Northwood University studying marketing and finance. “I am so grateful to be given the opportunity to attend the State of the State with my Grandpa,” Meghan said. “He has served his constituents with dignity and integrity and I am so proud of him.”######
Kenya’s Communications Authority has approved local telecom provider Safaricom’s application for licences to broadcast four TV channels, allowing the operator to create its own content for the IPTV service it launched in May, according to local reports.Safaricom’s broadcast licences will enable it to distribute content both over-the-air and online, as well as to compete with existing pay TV and multi-play operators, including Wananchi’s Zuku TV service.Safaricom began marketing an IP-enabled set-top, the BigBox, for KES10,000 (€88) plus a KES4,000 monthly fee for TV and 4G-enabled broadband services in May, with limited success.
Data will also be presented on potential risk factors for repeated or persistent hyperkalemia (Poster # SuMDP65). Source:https://www.astrazeneca.com/media-centre/press-releases/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-farxiga-in-patients-with-type-2-diabetes-to-be-featured-at-aha-01112018.html Whether clinical characteristics predicting bleeding and ischemic risk identify subgroups of patients who may derive benefit from long-term treatment with BRILINTA, with a lower risk of major bleeding (Poster #Sa2100) The effects of long-term use of BRILINTA in patients who have had a heart attack and who did not receive a coronary stent vs. those who did receive a coronary stent placement (Oral Presentation #102) The use of high-sensitivity cardiac troponin to identify patients who are at a higher-risk of major CV events (Oral Presentation #100) Reviewed by Alina Shrourou, B.Sc. (Editor)Nov 1 2018AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company’s Cardiovascular, Renal & Metabolism (CVMD) therapy area at the American Heart Association (AHA) Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.New evidence will build on broad clinical research from AstraZeneca that aims to help redefine the management of CVMD diseases and address the need for a more proactive and holistic approach to patient care. Presentations will include findings from some of the largest trials in broad patient populations with FARXIGA (dapagliflozin) in type 2 diabetes (T2D), BRILINTA (ticagrelor) in patients with a history of heart attack, and in hyperkalemia.Danilo Verge, Vice President, Cardiovascular, Renal & Metabolism, Global Medical Affairs, said: “An estimated 20 million people each year die from cardiovascular, renal and metabolic diseases, yet shared risk factors are frequently not diagnosed or addressed holistically. Our data at AHA reflect an integrated approach to managing the needs of patients living with type 2 diabetes and risk of cardiovascular or renal disease, and those with a history of cardiovascular disease at acute and long-term risk of recurrence. We stand firmly behind our mission to provide new solutions earlier in disease management to these patients at risk for multiple complications.”DECLARE-TIMI 58: a landmark CVOT evaluating CV risk in patients with T2DClinical trial results showing the safety and efficacy of FARXIGA vs. placebo on primary CV and secondary renal efficacy outcomes in adults with T2D who have multiple CV risk factors or established CV disease, will be presented in a late-breaking oral presentation (Late Breaking Abstract #19485). DECLARE-TIMI 58 evaluated the CV outcomes of FARXIGA vs. placebo over a period of up to five years, across 33 countries and in more than 17,000 adults with T2D with multiple CV risk factors or established CV disease.Related StoriesMetformin use linked to lower risk of dementia in African Americans with type 2 diabetesNew biomaterial could encapsulate and protect implanted insulin-producing cellsObese patients with Type 1 diabetes could safely receive robotic pancreas transplantIn September 2018, AstraZeneca announced that FARXIGA met its primary safety endpoint of non-inferiority for major adverse cardiovascular events (MACE) and achieved a statistically-significant reduction in the composite endpoint of hospitalization for heart failure (hHF) or CV death, one of the two primary efficacy endpoints. Additionally, fewer MACE events were observed with FARXIGA for the other primary efficacy endpoint, however, this did not reach statistical significance. Clinical trial results presented at AHA Scientific Sessions 2018 will include additional details on the primary CV safety and efficacy, as well as secondary renal efficacy outcomes from DECLARE-TIMI 58. FARXIGA is not indicated to reduce the risk of CV events, hHF or renal outcomes.Three new sub-analyses from the PEGASUS-TIMI 54 trial will also be presented. The trial compared BRILINTA (90mg or 60mg twice daily) plus aspirin vs. aspirin alone in 21,162 patients with prior (1 to 3 years) heart attack. The sub-analyses evaluate:
Source:Mary Ann Liebert, IncJournal reference:Kim, W. et al. (2019) Tissue-Engineered Esophagus via Bioreactor Cultivation for Circumferential Esophageal Reconstruction. Tissue Engineering. doi.org/10.1089/ten.tea.2018.0277 Dr. Chung and colleagues from Korea present an exciting approach for esophageal repair using a combined 3D printing and bioreactor cultivation strategy. Critically, their work shows integration of the engineered esophageal tissue with host tissue, indicating a clinically viable strategy for circumferential esophageal reconstruction.”John P. Fisher, PhD, Tissue Engineering Co-Editor-in-Chief, Fischell Family Distinguished Professor and Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland Reviewed by James Ives, M.Psych. (Editor)Jun 18 2019The loss of complete segments of the esophagus often results from treatments for esophageal cancer or congenital abnormalities, and current methods to re-establish continuity are inadequate. Now, working with a rat model, researchers have developed a promising reconstruction method based on the use of 3D-printed esophageal grafts. Their work is published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.Eun-Jae Chung, MD, PhD, Seoul National University Hospital, Korea, Jung-Woog Shin, PhD, Inje University, Korea, and colleagues present their research in an article titled “Tissue-Engineered Esophagus via Bioreactor Cultivation for Circumferential Esophageal Reconstruction”. The authors created a two-layered tubular scaffold with an electrospun nanofiber inner layer and 3D-printed strands in the outer layer. After seeding human mesenchymal stem cells on the inner layer, constructs were cultured in a bioreactor, and a new surgical technique was used for implantation, including the placement of a thyroid gland flap over the scaffold. Efficacy was compared with omentum-cultured scaffolding technology, and successful implantation and esophageal reconstruction were achieved based on several metrics.
Dropbox shares surged Friday as the cloud data storage firm made its Wall street debut following a public offering raising some $750 million. Citation: Cloud firm Dropbox surges in Wall Street debut (Update) (2018, March 23) retrieved 18 July 2019 from https://phys.org/news/2018-03-cloud-firm-dropbox-surges-wall.html Dropbox raises price range ahead of stock debut Explore further Shares trading under the symbol DBX rallied 35.6 percent to close at $28.48, with intraday gains as much as 50 percent, following the offering price of $21.The initial public offering was the biggest in the technology sector since Snapchat’s in 2017 and is among the few “unicorns”—venture-funded startups worth more than $1 billion—to go public.The strong demand suggested not all tech companies have been hit by the events of this week, when big players, especially in social media, have seen their shares dive following reports that a data analysis firm hired by Donald Trump’s presidential campaign misused personal information of some 50 million Facebook users.Created in 2007, Dropbox is one of a number of tech firms centered around the internet “cloud,” allowing users to store data for remote access by any internet-linked devices.Storing digital data from music and films to documents, presentations and images has become big business with the lifestyle shift to accessing content and services online.Its market value for the initial public offering was some $8 billion. © 2018 AFP This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
© 2018 The Associated Press. All rights reserved. A Harvard University forum is examining how a recent death linked to self-driving technology is causing concern about safety. Toyota suspends self-driving car tests after Uber death Explore further Citation: Harvard forum examining safety of self-driving vehicles (2018, May 4) retrieved 18 July 2019 from https://phys.org/news/2018-05-harvard-forum-safety-self-driving-vehicles.html In this Tuesday, Jan. 10, 2017, file photo, an autonomous vehicle is driven by an engineer on a street in an industrial park in Boston. Harvard University’s School of Public Health is holding a forum on Friday, May 4, 2018, to examine how recent deaths linked to self-driving technology are causing concern about safety, and raising questions about whether the field is moving too quickly. (AP Photo/Steven Senne, File) This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Friday’s panel discussion at Harvard’s T.H. Chan School of Public Health is exploring whether the field is advancing too quickly.Some experts are pointing to the March death of a pedestrian struck by a self-driving Uber vehicle in Tempe, Arizona, as cause for serious safety concern. It was the first death involving a fully autonomous test vehicle.Current federal regulations have few requirements specifically for self-driving vehicles, leaving it for states to handle.Participants will include Deborah Hersman, president and CEO of the National Safety Council, and John Leonard, vice president of research at the Toyota Research Institute. Toyota has been working with Uber on driverless systems.